February 14, 2023
But new developments may be on the horizon. A pair of studies published in early February from researchers at the biotech startup AcuraStem and the University of Southern California validated two potential drug targets in animal models of both genetic and sporadic ALS, paving the way for broad treatments.
“I think there are some very promising drug candidates that really seem to change the disease course in the known genetic forms of the disease,” Justin Ichida, Ph.D., senior author of the studies and co-founder of AcuraStem, told Fierce Biotech Research in an interview. “But we were hoping to find ways to have that kind of transformative potential for the larger patient population for whom we don’t know their genetic causes.”
The first study, published Feb. 2 in Cell Stem Cell, showed that suppressing the gene SYF2 boosted the survival of motor neurons grown from the stem cells from patients with either genetic or sporadic ALS. Their analyses showed that SYF2 was manipulating the protein TDP-43, which is thought to drive pathology in both forms of the condition due to being misplaced in the cytoplasm of motor cells rather than the nucleus. Experiments in mouse models of genetic and sporadic ALS also showed that SYF2 suppression improved motor function and reduced neurodegeneration.
The second study, published Feb. 7 in Cell, was more expansive: The researchers used a drug called apilimod to inhibit the enzyme PIKFYVE in human motor neurons, roundworms, fruit flies and mice with genetic or sporadic ALS. In this case, the drug prompted motor neurons to clear out toxic proteins, improving motor function and extending survival in all the models.
While the SYF2 findings are new, PIKFYVE has been a target of interest for ALS for a while by AcuraStem as well as Verge Genomics. “The research published in Cell further validates PIKFYVE as a promising therapeutic target in ALS and sheds light on a novel mechanism for clearing pathological protein aggregates,” Robert Scannevin, Ph.D., chief scientific officer at Verge, said in an emailed response to a request for comment. “Verge identified PIKFYVE as a target in our CONVERGE platform, and it is encouraging to see robust, independent validation across a number of sporadic and familial in vitro and in vivo ALS models.”
Read the full article from FierceBioTech.com
Inflammation, Neuroscience, Rare/Orphan
University of Southern California
2018 Harrington Rare Disease